Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NanoViricides Inc NNVC

Healthcare Biotechnology
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other... see more

Recent & Breaking News (NYSEAM:NNVC)

NanoViricides Files Quarterly Report for Period Ending September 30, 2018

PR Newswire November 26, 2018

NanoViricides, Inc. Appoints Mr. James Sapirstein to its Board of Directors

PR Newswire October 29, 2018

NanoViricides CEO Dr. Irach Taraporewala Presents a Letter to Shareholders

PR Newswire October 22, 2018

NanoViricides Has Filed its Annual Report, Company Reports Strong Progress in Advancement of HerpeCide Program

PR Newswire October 15, 2018

NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1

PR Newswire September 28, 2018

NanoViricides Inc. to Present at 20th Annual Rodman & Renshaw Conference in NYC on Sept 6th

PR Newswire September 5, 2018

NanoViricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study

PR Newswire August 7, 2018

NanoViricides, Inc. Welcomes Dr. Irach Taraporewala as the New CEO

PR Newswire July 23, 2018

NanoViricides Provides Update on Recent Events

PR Newswire July 12, 2018

Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research

PR Newswire June 26, 2018

NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today

PR Newswire April 9, 2018

NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin

PR Newswire March 19, 2018

NanoViricides Files Quarterly Report for Period Ending December 31, 2017

PR Newswire February 21, 2018

Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

PR Newswire December 6, 2017

NanoViricides Files Quarterly Report for Period Ending September 30, 2017

PR Newswire November 20, 2017

NanoViricides Signs Extension of Herpes Virus (HSV) Testing Agreement with University of Wisconsin

Accesswire November 8, 2017

NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

PR Newswire November 6, 2017

Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center

PR Newswire October 26, 2017

NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

PR Newswire October 17, 2017

NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials

PR Newswire September 29, 2017